QUEEN MARY UNIVERSITY OF LONDON (QMUL) is one of the UK’s leading research-intensive higher education institutions and part of the Russell group. QMUL is in the top 120 University in the world in the QS World University Rankings. The innovative research environment of QMUL and close collaboration with Barts Health NHS Trust and healthcare partners across East London gives QMUL a unique opportunity to translate and extend basic and clinical research into therapeutics that benefit the local community and beyond. QMUL has 112 H2020 participations currently, including R&D projects, as partner and coordinator under the societal challenges pillar, including SC1 Health.
Main tasks in the project
In WP2, QMUL, co-leader, will be primarily involved providing clinical expertise in driving and management of recruitment of patients with RA, SS and SLE to the clinical studies as well as provide clinical insights to the data analysis emerging from the clinical studies. Patients enrolled will be part of highly characterised clinical cohorts with well-established longitudinal datasets and associated biological samples stored in a large HTA-approved biobank.
In WP6, QMUL will work closely with the lead partner, all the other clinical partners, the patient advisory board and all the relevant patients’ organizations in order to ensure effective recruitment, adherence to GCP and retention of participants in the clinical validation study.
In WP9, QMUL will ensure, together with all the other clinical partners that dissemination of the project’s results will result in maximum impact on all the beneficiaries of this project, including the stakeholders, the academic community, patients and the general public. QMUL will participate to conferences and workshops, events to promote dissemination of the results, and will actively contribute to the publications of research results.
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 853981. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and PARKINSON’S DISEASE SOCIETY OF THE UNITED KINGDOM LBG.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.